Efficacy and safety of clopidogrel in children with diarrhea associated hemolytic uremic syndrome

Oxidative Dehydrogenative Coupling of Thiols with Alkanes for the Synthesis of Sulfoxides

An oxidative dehydrogenative coupling of thiols with alkanes via direct C(sp³)-H bond functionalization to form a new C-S bond and S═O double bond was developed. The present reaction features the use of readily available reagents and high step- and atom-efficiency, thus providing an efficient access to sulfoxides. A possible mechanism is proposed.

Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome

BACKGROUND

Typical hemolytic uremic syndrome (HUS) causes acute kidney injury (AKI) and serious sequelae of chronic kidney disease (CKD) in some. Hyperuricemia is a common finding in typical HUS that may contribute to kidney damage. We explored whether aggressive management of hyperuricemia with rasburicase could improve outcomes in AKI patients with typical HUS.

METHODS

We retrospectively analyzed medical records of children with typical HUS admitted to a tertiary center between 2005 and 2017. We compared clinical outcomes of hospitalization and 1-year post-discharge between those with rasburicase treatment (n = 13) and those without (controls, n = 29).

RESULTS

With rasburicase treatment, hyperuricemia corrected more rapidly (median 36 vs. 120 h, p < 0.001), and hospital stays were shorter (median 9 vs. 12 days, p = 0.003) than in the controls. There was no difference in dialysis requirement. At 1-year post-discharge, the proportion of patients with impaired kidney function (estimated glomerular filtration rate < 90 mL/min/1.73 m²) was lower in the rasburicase group (7.7% vs. 41.4%, p = 0.036) than in the controls. Hypertension and proteinuria tended to be more common in the controls than in the rasburicase group. Collectively, long-term renal sequelae of impaired kidney function, proteinuria, or hypertension at a 1-year follow-up was less common in the rasburicase group than in the controls (7.7% vs. 62.1%; p = 0.001).

CONCLUSIONS

Children with typical HUS treated with rasburicase had shorter hospital stays and less long-term sequelae at 1-year post-discharge than those who were not treated with rasburicase. These results support the use of rasburicase to prevent CKD in pediatric patients with typical HUS-associated AKI. Graphical Abstract.

Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome

BACKGROUND

Platelet transfusions should be avoided in children with post-diarrheal hemolytic uremic syndrome (D + HUS) because they might increase microthrombi formation, thereby aggravating the disease. As this possibility has not yet been explored, we investigated whether platelet transfusion in patients with D + HUS would lead to a worse disease course compared to that in patients who did not receive platelet transfusion.

METHODS

This was a case-control study in which data from D + HUS children who received platelet transfusions (cases, n  =  23) and those who did not (controls, n  =  54) were retrospectively reviewed and compared.

RESULTS

Both patient groups were similar in age (p = 0.3), gender (p  =  0.53), weight (p  =  0.86), height (p  =  0.45), prior use of non-steroidal anti-inflammatory drugs (p  =  0.59) or antibiotics (p  =  0.45) and presence of dehydration at admission (p  =  0.79). The two groups also did not differ in initial leukocyte count (p  =  0.98), hematocrit (p  =  0.44) and sodium (p  =  0.11) and alanine aminotransferase levels (p  =  0.11). During hospitalization, dialysis duration (p  =  0.08), number of erythrocyte transfusions (p  =  0.2), serum creatinine peak (p  =  0.22), presence of severe bowel (p  =  0.43) or neurologic (p  =  0.97) injury, arterial hypertension (p  =  0.71), need for intensive care (p  =  0.33) and death (p  =  1.00) were also comparable.

CONCLUSION

Our findings suggest that platelet transfusion does not aggravate the course of the disease. Conversely, no hemorrhagic complications were observed in the group of patients who did not receive a platelet transfusion. Until these observations are confirmed by further studies, the benefits and risk of platelet transfusion should be thoughtfully balanced on an individual case basis.